Clinical variables in hyperestrogenism and hypogonadism in obese patients from a south american hospital

Jorge Hernandez; Juan Theran; Valentina Ochoa; Valentina Navas; Pinzon Harold Torres; Jaime Gomez; Luis Dulcey

doi:10.1530/endoabs.109.EP26

EP26

Prev Next

Section Contents Cite

Endocrine Abstracts (2025) 109 EP26 | DOI: 10.1530/endoabs.109.EP26

SFEBES2025 ePoster Presentations Metabolism, Obesity and Diabetes (14 abstracts)

Clinical variables in hyperestrogenism and hypogonadism in obese patients from a south american hospital

Jorge Hernández ¹ , Juan Theran ¹ , Valentina Ochoa ¹ , Valentina Navas ¹ , Harold Torres Pinzon ¹ , Jaime Gómez ² & Luis Dulcey ³

Author affiliations

¹University of Santander, Bucaramanga, Colombia; ²Autonomous University of Bucaramanga, Bucaramanga, Colombia; ³University of Andes, Mérida, Venezuela

Introduction: Epidemiological data on the incidence of hyperestrogenism is scarce and is typically assessed indirectly through the prevalence of gynecomastia.

Objective: To evaluate the prevalence of hyperestrogenism, androgen deficiency, and the combination of testosterone deficiency with hyperestrogenism in obese men through a retrospective analysis. The study also examines the influence of body mass index (BMI) and age on estradiol and testosterone levels.

Materials and Methods: A retrospective review of 100 medical records from men categorized as normal weight, overweight, or obese was conducted. The statistical analysis was performed using IBM SPSS Statistics 23.0.

Results: Hyperestrogenism was diagnosed in 34% of patients, based on estradiol levels exceeding 47 pg/ml. As BMI increased, the incidence of hyperestrogenism rose from 19% in men with normal BMI to 42% in those with grade III obesity. Testosterone deficiency was observed in 61% of patients. A significant reduction in blood testosterone levels was noted as BMI increased, from 12.5 nmol/l in men with normal BMI to 8.6 nmol/l in those with grade III obesity. The combination of testosterone deficiency and hyperestrogenism was present in 58% of the patients examined.

Discussion: The study highlights the significant impact of hormonal imbalances, particularly hyperestrogenism and hypogonadism, in obese patients. These conditions are associated with reduced quality of life, sexual performance, and an increased cardiometabolic risk, aligning with findings from other studies.

Conclusion: Hormonal conditions such as hypogonadism and hyperestrogenism play a critical role in the health of obese patients, contributing to significant declines in quality of life and increased cardiometabolic risk.